FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

AMPYRA BREAKING NEWS: This article was just published & contains the best info & explanations I've seen yet! (Stan)

Studies have shown that patients treated with Ampyra (dalfampridine), 10 mg twice daily, improve on timed 25-ft walks. It is the first drug with an indication to improve walking speed in multiple sclerosis.


"A 25-ft walking test might not sound like a big deal, but it can have huge implications for patients and their caregivers," Dr. Burks added. 






Read more »

Labels: ,


 

Multiple Sclerosis research showing promise: Canadian stem cell study

(Posted By: Josi Creek)
Read more »

 

Women's tour caddy walks away her MS


(Posted by- Desinie Smith)

 

What's new on Multiple Sclerosis on PubMed

Thursday

 

Study Says Babies born in summer ‘more likely to develop multiple sclerosis’

(Posted By: Josi Creek)


Read more »

 

Low Vitamin D Levels Are Related to MS Brain Atrophy, Cognitive Function, Studies Show

(Posted by-Desinie Smith)

Labels:


 

Extension Data Show Dalfampridine (Amprya) Continues to be Beneficial in Multiple Sclerosis

(Posted By: Josi Creek)


Read more »

Labels:


 

A breakthrough finding may lead to earlier diagnosis, more effective intervention & even a cure for Multiple Sclerosis

(Posted By: Josi Creek)
Read more »

Labels: ,


 

In the 1st sequencing of twin genomes researchers searched into the genetics of multiple sclerosis, coupling DNA sequencing with a look at the regulation & expression of genes, only to come up empty-handed

(Posted By: Josi Creek)















Read more »

Labels:


Wednesday

 

The Answers to Frequently Asked Questions About Ampyra

( Posted by-Desinie Smith)
Read more »

Labels: ,


Tuesday

 

Gilenya and fingolimod are the same thing, the Novartis drug FTY720

(Posted By: Josi Creek)
Read more »

Labels:


 

Icahn aims to help fix what is "broken" at Genzyme: It expects to be fined at least $175 million by U.S. regulators for manufacturing violations"

(Posted By: Josi Creek)

Read more »

 

Voice-controlled wheelchairs for care homes in development by MIT


(Posted By: Josi Creek)

Labels: ,


 

FREE DOWNLOAD OF THIS NEW BOOK: "MS & me -a guide to living with MS" contains practical tips including setting goals, problem solving & healthy living-Plus it explores how by monitoring their own MS people build a better understanding of what might trigger symptoms!

(Posted By: Josi Creek)

 

Opexa Strengthens Management Team with Hire of Cell Therapy Expert

(Posted By: Josi Creek)

Labels:


 

NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center

(Posted By: Josi Creek)

Labels:


 

What's new from the American Academy of Neurology on Multiple Sclerosis

( Posted by-Desinie Smith)
Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk
K.C. Simon, ScD, I.A.F. van der Mei, PhD, K.L. Munger, ScD, A. Ponsonby, MD, PhD, J. Dickinson, PhD, T. Dwyer, MD, P. Sundström, MD, PhD and A. Ascherio, MD, DrPH

The Multiple Sclerosis Functional CompositeA clinically meaningful measure of disability
Chris H. Polman, MD and Richard A. Rudick, MD

Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity
Laura J. Balcer, MD, MSCE and Elliot M. Frohman, MD, PhD

Freedom from disease activity in multiple sclerosis
Eva Havrdova, MD, Steven Galetta, MD, Dusan Stefoski, MD and Giancarlo Comi, MD

Labels:


 

What's New in PubMed on Multiple Sclerosis

( Posted by-Desinie Smith)
Detection of viral DNA sequences in the cerebrospinal fluid of patients with multiple sclerosis.
Mancuso R, Hernis A, Cavarretta R, Caputo D, Calabrese E, Nemni R, Ferrante P, Delbue S, Clerici M.

Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.Tselis A.

Genome-wide association study of circulating vitamin D levels.Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, Albanes D.

Role of MRI in diagnosis and treatment of multiple sclerosis.Sahraian MA, Eshaghi A.

Antiphospholipid syndrome and central nervous system.Mayer M, Cerovec M, Radoš M, Cikeš N.

99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence.Ascherio A, Munger KL.

99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections.Getts MT, Miller SD

Hyperbaric oxygen therapy for multiple sclerosis.Bennett M, Heard R.

Labels:


Monday

 

Greeley Neurologist Has MS In Common With Patients


(Posted By: Josi Creek)

 

Court orders bail for man jailed over medical marijuana

(Posted By: Josi Creek)

Labels:


 

Mayo Clinic Research Provides New Insight Into Tissue Damage In Multiple Sclerosis

( Posted by-Desinie Smith)

 

Canine companion and Lifeline alarm bring independence to multiple sclerosis patient


(Posted By: Josi Creek)

Labels:


 

Acorda Therapeutics Chief Scientific Officer Andrew R. Blight Receives Purchase College Science Entrepreneurship Award

(Posted By: Josi Creek)

Labels:


 

Safemedtrip launches facilitation service for CCSVI, Liberation Procedure for Multiple Sclerosis at top Indian Hospital.

(Posted By: Josi Creek)

Labels:


 

Internet shifts patient-doctor power structure



(Posted By: Josi Creek)

 

Neurologists Eagerly Await New Oral Treatment Options for Multiple Sclerosis Such as EMD Serono's Movectro, Extavia, & Novartis's Gilenya

(Posted By: Josi Creek)


Read more »

Labels: , , , , , ,


Sunday

 

What's New in PubMed on Multiple Sclerosis

( Posted by-Desinie Smith)
Targeting receptor antibodies in immune cardiomyopathy.Jahns R, Schlipp A, Boivin V, Lohse MJ

New drug therapies for multiple sclerosis.Mangas A, Coveñas R, Geffard M.

Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain.Mattsson N, Johansson P, Hansson O, Wallin A, Johansson JO, Andreasson U, Andersen O, Haghighi S, Olsson M, Stridsberg M, Svensson J, Blennow K, Zetterberg H.

Structural and functional hippocampal changes in multiple sclerosis patients with intact memory function.Roosendaal SD, Hulst HE, Vrenken H, Feenstra HE, Castelijns JA, Pouwels PJ, Barkhof F, Geurts JJ.

Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices.Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, Kennedy TE, Antel JP.

NEUROBID-an EU-funded project to study the developing brain barriers.Bueter W, Saunders NR, Mallard C, Bauer HC, Stolp HB, Kavelaars A, Dammann O

Regionally Distinct White Matter Lesions Do Not Contribute to Regional Gray Matter Atrophy in Patients with Multiple Sclerosis.Antulov R, Carone DA, Bruce J, Yella V, Dwyer MG, Tjoa CW, Benedict RH, Zivadinov R.

Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity.Saini H, Fernandez G, Kerr D, Levy M.

Labels:


 

Clinic shuts doors after CBS 60 Minutes accuses it of selling "21st Century snake oil" to MS patients! It claimed stem-cell treatments could cure their MS

(Posted By: Josi Creek)

...according to CBS, Stowe has been selling `21st Century snake oil’ to patients and claimed that stem-cell treatments could cure Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), multiple sclerosis, cancer and Parkinson’s disease. The brochure falsely claims Stowe has an “FDA-approved stem cell based approach to regenerative healing” and projects a net income of $71 million by the third year of operation for Stowe Foundation, a nonprofit started in 2003.



Read more »

Labels:


Saturday

 

British Researchers to Study Effects Posed by Cellphone Usage

(Posted By: Josi Creek)

Labels:


 

Muzzling killer T-cells may ease multiple sclerosis

(Posted by-Desinie Smith )

Friday

 

What's New in PubMed on Multiple Sclerosis

(Posted by-Desinie Smith)
Alzheimer drug worsens neurological dysfunction in multiple sclerosis.
[No authors listed]

Role of Cytokines as Mediators and Regulators of Microglial Activity in Inflammatory Demyelination of the CNS.Merson TD, Binder MD, Kilpatrick TJ.

Clinical practice improvement approach in multiple sclerosis rehabilitation: a pilot study.Khan F, Pallant JF, Zhang N, Turner-Stokes L

Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration.Green AJ, McQuaid S, Hauser SL, Allen IV, Lyness R.

Applying functional MRI to the spinal cord and brainstem.Leitch JK, Figley CR, Stroman PW.

Elevated plasma C4a levels in multiple sclerosis correlate with disease activity.Ingram G, Hakobyan S, Robertson NP, Morgan PB

Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
Doggrell SA.

Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.Bains SN, Hsieh FH, Rensel MR, Radojicic C, Katz HT, Inamdar SR, Lang DM.
Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells.Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, Kumanogoh A, Kajiyama K, Yoshikawa H, Sakoda S.

Labels:


 

Spinal Cord Injury: Hope of New Treatment

( Posted by-Desinie Smith)

Labels:


 

UBS puts 'sell' tag on Elan over Tysabri fears

(Posted By: Josi Creek)

Labels:


 

What's new in Radiology on Multiple Sclerosis

(Posted by-Desinie Smith)
Structural and Functional Hippocampal Changes in Multiple Sclerosis Patients with Intact Memory Function Stefan D. Roosendaal, Hanneke E. Hulst, Hugo Vrenken, Heleen E. M. Feenstra, Jonas A. Castelijns, Petra J. W. Pouwels, Frederik Barkhof, and Jeroen J. G. Geurts

Labels:


 

Acorda Therapeutics to Host Conference Call to Report First Quarter 2010 Financial Results on April 30, 2010

(Posted By: Josi Creek)

 

Four Standard-Bearers For Stem Cell Therapies

(Posted By: Josi Creek)

Labels:


 

Multiple Sclerosis researcher wins national award

(Posted By: Josi Creek)

Labels:


 

Vatican to provide millions for adult stem- cell research

(Posted By: Josi Creek)

Labels:


 

Novartis To Cut Pharmaceutical Jobs

(Posted By: Josi Creek)

 

Copaxone and Avonex in the Treatment of Multiple Sclerosis To Diminish Following the Launch of Oral Disease-Modifying Therapies

( Posted by-Desinie Smith)
From the article," According to the report, 48 and 43 percent of surveyed neurologists expect to decrease their first-line use of Copaxone and Avonex, respectively, by 2012, while 45 and 38 percent of respondents expect to increase their third-line use of each respective therapy. Meanwhile, approximately half of surveyed neurologists do not expect to adjust their prescribing of Copaxone, Avonex or any other IFN-beta therapies in any line of treatment over the next two years."

Labels: ,


Thursday

 

What's New on Multiple Sclerosis in PubMed

(Posted by-Desinie Smith)
Immunization with pVAXhsp65 Decreases Inflammation and Modulates Immune Response in Experimental Encephalomyelitis.
Gonçalves Zorzella-Pezavento SF, Chiuso-Minicucci F, Donegá França TG, Lumi Watanabe Ishikawa L, Rodrigues Martins D, Lopes Silva C, Sartori A

Multiple sclerosis impairs ability to detect abrupt appearance of a subliminal stimulus.Carrubba S, Minagar A, Gonzalez-Toledo E, Chesson AL Jr, Frilot C 2nd, Marino AA.

Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis.Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ

Betaferon in the treatment of multiple sclerosis.Vidović M, Sinanović O, Burina A, Hudić J, Sehanović A

[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis]Elovaara I, Atula S, Erälinna JP, Färkkilä M, Pirttilä T, Remes A, Ruutiainen J, Varis T; Suomalaisen Lääkäriseuran Duodecimin; Suomen Neurologisen Yhdistyksen Asettama Työryhmä.

Labels:


 

High hopes for MS research

( Posted by-Desinie Smith)
From the article, "Many of the 100 pairs of ears in the Earl Grey room hung on Thornton's words. Minutes after his veins were opened in a $10,000 balloon angioplasty procedure last month, he said, he had warm fingers. Warm toes. And now, more energy than he'd had in almost 25 years. After Thornton finished telling this to the Earl Grey crowd, hands shot up. "Before your treatment, could you stand on that chair the way you're doing?" asked Cathi Sleva, who came to the meeting to support a friend with MS."Not without falling over," Thornton said quietly. "

Labels:


 

Good result helps Elan's plans to post first annual profit in a decade (Tysabri)

(Posted By: Josi Creek)

Labels:


 

Biogen Idec revenues increas in first quarter

(Posted By: Josi Creek)

Labels:


 

Novartis Racing To Be First with Oral MS Drug

( Posted by-Desinie Smith)

Labels:


 

Studies from Various Medical Journals

( Posted by-Desinie Smith)
Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration
Ari J. Green, Stephen McQuaid, Stephen L. Hauser, Ingrid V. Allen and Roy Lyness

Labels:


Wednesday

 

Drugmaker Elan posts narrower loss in 1st quarter

(Posted By: Josi Creek)

 

New procedure can leave mutant cell structures behind, protecting babies from disease

(Posted By: Josi Creek)

Labels:


 

Neurologists Debating Statins in Multiple Sclerosis-The hypothesis is that popular cholesterol-lowering agents such as Lipitor may also play a role in immunomodulation, but demonstrating this link has proven tricky


April 21, 2010 (Toronto, Ontario) — Evidence is slim, but many neurologists remain hopeful there will one day be a role for statins in treating multiple sclerosis. Here at the American Academy of Neurology 62nd Annual Meeting, investigators weighed the possible benefits and risks.
Read more »

Tuesday

 

Biogen added 1500 new Tysabri patients in the 1st quarter compared to 2,600 patients in the 4th quarter last year-This is the 3rd quarter in a row of declining patient growth

Tysabri's label was recently changed to indicate that the longer patients remain on the drug, the greater their risk of a potentially deadly brain infection called progressive multifocal leukoencephalopathy (PML). Even though Tysabri is a more effective drug, patients are comfortable with inferior but safer options such as Teva Pharmaceutical's Copaxone, Novartis'  Extavia, and Rebif from Pfizer.









Read more »

Labels: , , , , ,


 

CCSVI: Experts Say Using Angioplasty to Treat Multiple Sclerosis Should Only Be Done in Clinical Trials


April 19, 2010 (Toronto) -- People with Multiple Sclerosis (MS) should not undergo a controversial new treatment that's based on the theory that blocked neck veins can trigger MS, experts say.
Neither the theory nor the treatment -- using angioplasty to open up the narrowed veins -- has been proved in large numbers of people, says Robert Zivadinov, MD, PhD, a researcher at the State University of New York in Buffalo who is studying the approach.
"There are no data at this moment to determine whether this is useful," 
Read more »

 

Biogen profit slips on health-reform charge

(Posted By: Josi Creek)

 

Novartis Posts Strong 1Q

(Posted By: Josi Creek)

 

Biogen profit, Tysabri sales disappoint

(Posted By: Josi Creek)

Labels:


 

Novartis to cut about 20 percent of U.S. jobs

(Posted By: Josi Creek)

 

What's New on Multiple Sclerosis in PubMed

( Posted by-Desinie Smith)
Subvocal articulatory rehearsal during verbal working memory in multiple sclerosis
Sweet LH, Vanderhill SD, Jerskey BA, Gordon NM,Paul RH, Cohen RA

Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal Leukoencephalopathy
Marshall LJ, Major EO

Studies in the Modulation of Experimental Autoimmune Encephalomyelitis.
Libbey JE, Tsunoda I, Fujinami RS

TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.
Lagier-Tourenne C, Polymenidou M, Cleveland DW.

The effect of textured insoles on gait patterns of people with multiple sclerosis.
Kelleher KJ, Spence WD, Solomonidis S, Apatsidis D.

IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cells.
Weiss N, Deboux C, Chaverot N, Miller F, Baron-Van Evercooren A, Couraud PO, Cazaubon S.
A diminished response to formalin stimulation reveals a role for the glutamate transporters in the altered pain sensitivity of mice with experimental autoimmune encephalomyelitis (EAE).
Olechowski CJ, Parmar A, Miller B, Stephan J, Tenorio G, Tran K, Leighton J, Kerr BJ
Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis
Bitan M, Weiss L, Reibstein I, Zeira M, Fellig Y,Slavin S, Zcharia E, Nagler A, Vlodavsky I.

Impaired information processing speed and attention allocation in multiple sclerosis patients versus controls: A high-density EEG study.Whelan R, Lonergan R, Kiiski H, Nolan H, Kinsella K, Hutchinson M, Tubridy N, Reilly RB
Downregulation of IL-17 and IFN-gamma in the optic nerve by beta-elemene in experimental autoimmune encephalomyelitis.
Zhang R, Tian A, Shi X, Yu H, Chen L.
An exploratory study on emotion recognition in patients with a clinically isolated syndrome and multiple sclerosis.
Jehna M, Neuper C, Petrovic K, Wallner-Blazek M, Schmidt R, Fuchs S, Fazekas F, Enzinger C
The changing demographic pattern of multiple sclerosis epidemiology.Koch-Henriksen N, Sørensen PS.
In Vivo multislice mapping of myelin water content using T(2)* decay.
Hwang D, Kim D, Du YP.
Kinetics of IL-17- and Interferon-gamma-producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLPp/IFA with pertussis toxin in SJL mice.
Hofstetter HH, Forsthuber TG.
Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.
Johnson KP.
Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.Saval A, Chiodo AE.

Labels: , ,


 

Copaxone Still an Option for Many

( Posted by-Desinie Smith)

Labels:


 

What's New on Multiple Sclerosis in PubMed

( Posted by-Desinie Smith)
Iron Status in Children With Recurrent Episodes of Tumefactive Cerebral Demyelination
van Toorn R, Schoeman JF, Solomons R, Rensburg MA, van Rensburg SJ

No evidence for an effect of DNA methylation on multiple sclerosis severity at HLA-DRB1*15 or HLA-DRB5
Handel AE, De Luca GC, Morahan J, Handunnetthi L, Sadovnick AD, Ebers GC, Ramagopalan SV

Factors influencing the health-related quality of life in Hungarian multiple sclerosis patients
Füvesi J, Bencsik K, Losonczi E, Fricska-Nagy Z, Mátyás K, Mészáros E, Benedek K, Rajda C, Lencsés G, Vécsei L

Evaluating the effects of estradiol on endothelial nitric oxide stimulated by erythrocyte-derived ATP using a microfluidic approach
Letourneau S, Hernandez L, Faris AN, Spence DM

Midbrain Cleft as a Cause of Chronic Internuclear Ophthalmoplegia, Progressive Ataxia, and Facial Weakness
Ahmad O, Reddel S, Lueck CJ

TGF-{beta} Enhances Effector Th1 Cell Activation but Promotes Self-Regulation via IL-10
Huss DJ, Winger RC, Peng H, Yang Y, Racke MK, Lovett-Racke AE

Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis
Audoin B, Zaaraoui W, Reuter F, Rico A, Malikova I, Confort-Gouny S, Cozzone PJ, Pelletier J, Ranjeva JP

A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation
Gierse JK, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, Johnston A, Murphy M, Nemirovskiy O, Ogawa S, Pegg L, Pelc M, Prinsen M, Schnute M, Wendling J, Wene S, Weinberg R, Wittwer A, Zweifel B, Masferrer J.

Overview of the biology of type I interferons
Kalliolias GD, Ivashkiv LB.

Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death
Carlson NG, Rojas MA, Redd JW, Tang P, Wood B, Hill KE, Rose JW.

["Chronic cerebrospinal venous insufficiency" and multiple sclerosis : Critical analysis and first observation in an unselected cohort of MS patients.]
Krogias C, Schröder A, Wiendl H, Hohlfeld R, Gold R.
Nervenarzt

Does hippotherapy improve balance in persons with multiple sclerosis: a systematic review
Bronson C, Brewerton K, Ong J, Palanca C, Sullivan SJ

Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis
Ramgolam VS, Markovic-Plese S.

Pathogenic mechanisms and experimental models of multiple sclerosis
Slavin A, Kelly-Modis L, Labadia M, Ryan K, Brown ML.

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study
Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A.

The antibody response to oligodendrocyte specific protein in multiple sclerosis
Aslam M, Kalluri SR, Cepok S, Kraus V, Buck D, Srivastava R, Hemmer B

Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis
Hirotani M, Niino M, Fukazawa T, Kikuchi S, Yabe I, Hamada S, Tajima Y, Sasaki H.

Thymic involution and proliferative T-cell responses in multiple sclerosis
Duszczyszyn DA, Williams JL, Mason H, Lapierre Y, Antel J, Haegert DG.

Regulatory T cells inhibit T cell proliferation and decrease demyelination in mice chronically infected with a coronavirus.
Trandem K, Anghelina D, Zhao J, Perlman S.

Development of an immunoassay for the detection of cystatin C dimers.Hyytiä H, Ristiniemi N, Airas L, Pettersson K, Hellman J.

Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.Bendfeldt K, Egger H, Nichols TE, Loetscher P, Denier N, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Gass A, Kappos L, Radue EW, Borgwardt SJ.

MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization.Jennewein C, von Knethen A, Schmid T, Brüne B.

Serum total cholesterol correlates positively to central serotonergic turnover in male but not in female subjects.
Markianos M, Koutsis G, Evangelopoulos ME, Sfagos C.

Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status
Matsushita T, Isobe N, Piao H, Matsuoka T, Ishizu T, Doi H, Masaki K, Yoshiura T, Yamasaki R, Ohyagi Y, Kira J.

IFN-beta reverses the lipopolysaccharide-induced proteome modifications in treated astrocytes
Vergara D, Martignago R, Bonsegna S, De Nuccio F, Santino A, Nicolardi G, Maffia M.

No evidence of association of the rare nsSNP rs35667974 in IFIH1 with multiple sclerosis
Bergamaschi L, Ban M, Leone MA, Sawcer SJ, D'Alfonso S.

Childhood cow's milk allergy and the risk of multiple sclerosis: a population based study
Ramagopalan SV, Dyment DA, Guimond C, Orton SM, Yee IM, Ebers GC, Sadovnick AD

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers
Ottervald J, Franzén B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellström S, Marko-Varga G, Végvári A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T.

Role of the innate immune system in the pathogenesis of multiple sclerosis
Gandhi R, Laroni A, Weiner HL.

Labels:


 

Art and Science of Nursing Care in Multiple Sclerosis

( Posted by-Desinie Smith)

Monday

 

Yale Chief Neurologist Honored For Multiple Sclerosis Genetic Breakthrough; Will Speak In Rocky Hill

(Posted By: Josi Creek)

Labels:


 

Novartis Races to Be First With Oral Multiple Sclerosis Drug

(Posted By: Josi Creek)

 

Elan Mulls Spinning Off Elan Drug Technologies

(Posted By: Josi Creek)
Irish drug maker Elan Corp. PLC (ELN) said Monday it's exploring the possibility of separating Elan Drug Technologies, or EDT, from its main business and creating two separate publicly-listed companies.
"The purpose of this exploration is to accurately assess the opportunity and impact on shareholder value," the company said in a statement, and a decision is expected in the coming months.

 

Dominance of Teva's Copaxone and Biogen Idec's AvonexTo Diminish Following the Launch of Oral Disease-Modifying Therapies

(Posted By: Josi Creek)

Labels: ,


 

Medical Conmen 21st Century Snake Oil Stem Cell

(Posted By: Josi Creek)

 

AAN: Rituximab Eyed for Secondary Progressive MS


( Posted by-Desinie Smith)

From the article," This study shows that rituximab could be an effective treatment in a subgroup of patients with secondary progressive multiple sclerosis," Carolina Ionete, MD, of the University of Massachusetts Medical School in Worcester, wrote in a poster presentation abstract for the annual meeting of the American Academy of Neurology."

Labels:


 

AAN: Switch from Interferon to Glatiramer Acetate Works in MS


( Posted by-Desinie Smith)

From the article, "TORONTO -- Multiple sclerosis patients who don't respond to or cannot tolerate treatment with interferon beta disease-modifying therapy can be safely and effectively switched to treatment with glatiramer acetate (Copaxone), researchers reported here."

Labels:


Sunday

 

AAN: Pregnant Women Opt to Stay on Copaxone


(Posted by-Desinie Smith)

From the article, " TORONTO -- Women with multiple sclerosis who opt to stay on glatiramer acetate (Copaxone) therapy while pregnant appear to have healthy children, doctors said here at the annual meeting of the American Academy of Neurology."

Labels:


 

New Data Supporting Cladribine Tablets as a Potential New Therapeutic Option Presented at the 62nd AAN Annual Meeting

( Posted by-Desinie Smith)
From the article, " Merck KGaA announced that new data providing further understanding on Cladribine Tablets as a potential new therapeutic option for relapsing forms of multiple sclerosis (MS) were presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN). "

 

AAN: Lowering Rituximab Dose Saves $$$ But Has Risks

(Posted By: Josi Creek)

 

AAN: MS-Related Fatigue Responds to Immunodulator

(Posted By: Josi Creek)

Saturday

 

AAN:Patient-reported Outcomes Study Shows Improvements In Quality Of Life Among Patients After 1 Year Of Treatment With TYSABRI

(Posted by-Desinie Smith)
From the article: "Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) who received 12 infusions of TYSABRI (natalizumab) reported improvements in quality of life (QoL) measures, as well as reduced fatigue and overall improved cognitive function, as measured by validated tools. The goal of the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, was to assess patient experiences with TYSABRI in a real-world setting. This research was presented in three posters at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists."

Labels:


Friday

 

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for Relapsing Remitting Multiple Sclerosis-AAN

( Posted by-Desinie Smith)
From the article, "These studies were presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN).
“As MS research progresses, emphasis will not only be on delaying disease progression, but on preventing permanent nerve damage”

 

Study doubts role for virus in multiple sclerosis

( Posted by-Desinie Smith )

Labels:


 

AAN: Alemtuzumab Maintains MS-Free Status Four Years-Plus

(Posted By: Josi Creek)

 

Lipitor and other Cholesterol Drugs May Help Treat Multiple Sclerosis

(Posted By: Josi Creek)

 

AAN:Acorda’s Ampyra Runs Ahead of Other Multiple Sclerosis Treatments

( Posted by-Desinie Smith )
From the article, "Ampyra is a new class of drug that isn’t made to slow the progression of MS like the other drugs on the market, but is meant to treat one of its most debilitating symptoms."

Labels: ,


 

AAN: Multiple Sclerosis Patients Visit ER for Non-MS Symptoms


( Posted by-Desinie Smith)

 

Significant Percentage Of Multiple Sclerosis Patients Receiving Alemtuzumab In Genzyme's Phase 2 Trial Remain Free Of Clinically-Active Disease

( Posted by- Desinie Smith)
More on the study between Rebif and Alemtuzumab here on WebMD. The findings were presented at the annual meeting of the American Academy of Neurology.

Labels: ,


 

Multiple Sclerosis research showcased at AAN meeting

 

Statin Drugs May Help Treat Multiple Sclerosis-From the AAN annual meeting

( Posted by-Desinie Smith)

Labels:


Wednesday

 

Opexa Presents Tovaxin® Data at the American Academy of Neurology 2010 Annual Meeting

(Posted By: Josi Creek)

 

Genzyme Says 71% Of Multiple Sclerosis Patient sReceiving Alemtuzumab In Mid-Stage Study Remain Free Of Clinically-Active Disease

(Posted By: Josi Creek)

Labels:


 

Acorda Therapeutics Announces Data On AMPYRA™ (dalfampridine) Presented At American Academy Of Neurology Meeting

( Posted by-Desinie Smith)

Labels: ,


 

Popular anticonvulsant drugs raise suicide risks-Neurontin and Trileptal

( Posted by-Desinie Smith)
(Reuters) - Widely used anticonvulsant drugs, including Pfizer's Neurontin and Novartis' Trileptal, may increase the risk of suicide, attempted suicide and violent death in patients taking them for the first time, U.S. researchers said.

Labels:


 

New Data Presented at American Academy of Neurology (AAN) Annual Meeting Show Additional Patient Benefits for Daily Multiple Sclerosis Pill Fingolimod

(Posted by-Desinie Smith)

Labels:


 

AAN: Caution Urged in Stenting Veins in Multiple Sclerosis Patients


( Posted by-Desinie Smith)

TORONTO -- Invasive procedures designed to correct venous blood flow in multiple sclerosis patients should not be performed until clinical trials can prove that the treatment is safe and effective, physicians here suggested.
John Corboy, MD, professor of neurology at the University of Colorado School of Medicine, Denver, reviewed studies performed by Paolo Zamboni, MD, professor of vascular surgery at the University of Ferrara in Italy. Zamboni has been the leading investigator into the possibility that chronic venous insufficiency could be a causative problem in multiple sclerosis.

Labels:


 

Studies from Various Medical Publications on Multiple Sclerosis

( Posted by -Desinie Smith )

Clinical Effect of Neutralizing Antibodies to Interferon Beta That Persist Long After Cessation of Therapy for Multiple Sclerosis
Laura F. van der Voort, MD; Francesca Gilli, PhD; Antonio Bertolotto, MD; Dirk L. Knol, PhD; Bernard M. J. Uitdehaag, MD, PhD; Chris H. Polman, MD, PhD; Joep Killestein, MD, PhD

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
Richard E Gonsette, Christian Sindic, Marie B D'hooghe, Peter-Paul De Deyn, Robert Medaer, Alex Michotte, Pierrette Seeldrayers, Daniel Guillaume

Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse
Eli Somer, Daniel Golan, Sara Dishon, Limor Cuzin-Disegni, Idit Lavi, and Ariel Miller

Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers
Mario HJ Vogt, Joop ten Kate, Roosmarie JM Drent, Chris H Polman, and Raymond Hupperts

Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters
Vijayshree Yadav, Gail H Marracci, Myrna Y Munar, Ganesh Cherala, Lauren E Stuber, Lilia Alvarez, Lynne Shinto, Dennis R Koop, and Dennis N Bourdette

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Mark S Freedman, Amit Bar-Or, Harold L Atkins, Dimitrios Karussis, Francesco Frassoni, Hillard Lazarus, Neil Scolding, Shimon Slavin, Katarina Le Blanc, Antonio Uccelli

TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis
Konstantinos Papadopoulos, Daniel J Tozer, Leonora Fisniku, Daniel R Altmann, Gerard Davies, Waqar Rashid, Alan J Thompson, David H Miller, and Declan T Chard

Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis
Luca Prosperini, Laura Leonardi, Paolo De Carli, Maria Letizia Mannocchi, and Carlo Pozzilli

Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing— remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy
Roberta Lanzillo, Giuseppe Orefice, Mario Quarantelli, Carlo Rinaldi, Anna Prinster, Gianluca Ventrella, Daniele Spitaleri, Giacomo Lus, Giovanni Vacca, Barbara Carotenuto, Elena Salvatore, Arturo Brunetti, Gioacchino Tedeschi, and Vincenzo Brescia Morra

Suppressive effect of glucocorticoids on TNF- production is associated with their clinical effect in multiple sclerosis
Lisa ML van Winsen, Chris H Polman, Christine D Dijkstra, Fred JH Tilders, and Bernard MJ Uitdehaag

Does MRI lesion activity regress in secondary progressive multiple sclerosis?
Y. Zhao, AJ Petkau, A. Traboulsee, A. Riddehough, and DKB Li

Validity of patient-derived disability and clinical data in multiple sclerosis
G. Ingram, E. Colley, Y. Ben-Shlomo, M. Cossburn, CL Hirst, TP Pickersgill, and NP Robertson

Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients
Michal Laron, Han Cheng, Bin Zhang, Jade S Schiffman, Rosa A Tang, and Laura J Frishman

Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis
Emma C Tallantyre, Lars Bo, Omar Al-Rawashdeh, Trudy Owens, Chris H Polman, James S Lowe, and Nikos Evangelou

Relationship of Cortical Atrophy to Fatigue in Patients With Multiple Sclerosis
Clelia Pellicano, MD; Antonio Gallo, MD, PhD; Xiaobai Li, PhD; Vasiliki N. Ikonomidou, PhD; Iordanis E. Evangelou, DPhil; Joan M. Ohayon, CRNP; Susan K. Stern, BS; Mary Ehrmantraut, CRNP; Fredric Cantor, MD; Henry F. McFarland, MD; Francesca Bagnato, MD, PhD

Interferon Neutralizing Antibodies in Multiple Sclerosis
J. Theodore Phillips

Mesenchymal stem cells for multiple sclerosis: can we find the answer?
Alan Tyndall

Labels:


Tuesday

 

Avanir’s Zenvia Drug Helps Control Involuntary Crying, Laughing

(Posted By: Josi Creek)

Labels:


 

AAN: No Pregnancy Issues in Early Natalizumab (Tysabri) Review

(Posted By: Josi Creek)

Labels:


 

RE-PLASTICISING THE BRAIN AND SPINAL CORD

(Posted By: Josi Creek)

Labels:


 

Stem cell research forges ahead in Ecuador

(Posted By: Josi Creek)

Labels:


 

Large Body of Data on TYSABRI(R) to Be Presented at Annual Meeting of the American Academy of Neurology

(Posted By: Josi Creek)

Labels:


 

Acorda Therapeutics Announces Data on AMPYRA(TM) (dalfampridine) Presented at American Academy of Neurology Meeting

(Posted By: Josi Creek)

Labels:


 

Gilenya Reduces Relapse Rates In Multiple Sclerosis Therapy: Novartis

(Posted By: Josi Creek)

Labels:


 

AAN: Multiple Sclerosis Patients Need Backup when Stopping Tysabri

( Posted by -Desinie Smith)

Labels:


 

Studies in Neurology on Multiple Sclerosis

( Posted by Desinie Smith )
A visual migraine aura locus maps to 9q21-q22
Tikka-Kleemola, PhD, V. Artto, MD, S. Vepsäläinen, MD, E.M. Sobel, PhD, S. Räty, BM, M.A. Kaunisto, PhD, V. Anttila, BM, E. Hämäläinen, BMLSc, M.-L. Sumelahti, MD, PhD, M. Ilmavirta, MD, PhD, M. Färkkilä, MD, PhD, M. Kallela, MD, PhD, A. Palotie, MD, PhD and M. Wessman, PhD

Diagnostic accuracy of confrontation visual field tests
N.M. Kerr, MBChB, S.S.L. Chew, MBChB, E.K. Eady, BSc(Hons), G.D. Gamble, BSc and H.V. Danesh-Meyer, MD

Impact of insurance status on migraine care in the United States -A population-based study Andrew Wilper, MD, MPH, Steffie Woolhandler, MD, MPH, David Himmelstein, MD and Rachel Nardin, MD

Labels:


Monday

 

AAN: Caution Urged in Stenting Veins in MS Patients (TORONTO)

(Posted By: Josi Creek)

Labels: ,


 

Shareholders expecting big quarter fromTysabri: sales soared 32% on a year-over-year basis.

(Posted By: Josi Creek)

Labels:


 

A doctor who exploited a group of "vulnerable" multiple sclerosis patients used stem cells which were not designed for human use

(Posted By: Josi Creek)

 

Teva Announces Copaxone(R) Reaches One Million Patient Years of Experience in the Treatment of Multiple Sclerosis

(Posted By: Josi Creek)

Labels:


 

Research Advocate: Ampyra Approved by FDA to Improve Walking for People with Multiple Sclerosis

(Posted by Desinie Smith )
This article on the NMSS's website has the phone number to call for info on Ampyra, how the medication works, the possible side effects and the cost.
The web page also has information on Benign MS, CCSVI, and migraines.
This web site also has more info on Ampyra.

Labels: , ,


Saturday

 

Why Multiple Sclerosis patients aren't waiting for proof-CCSVI


( Posted by -Desinie Smith)

CTV W5 presents this follow up report and video on CCSVI in Multiple Sclerosis patients.


"Dr. McDonald and his colleagues decided to unblock the vein with a small balloon, a procedure called a venoplasty.
"I had to tell Steve very specifically: I don't treat MS. I have no idea what effect the balloon angioplasty would have on MS, but I knew from studies that had been done that the abnormal flow characteristics warranted further investigation," Mc Donald says.
Steve says as soon as the vein was opened, he immediately felt warmth in the left side of his face and he could wiggle his toes.
"One of the nurses came over and said ‘Are you alright?' I said, ‘Yes, shake my hand.' She shook my left hand which was useless before," remembers Garvie.
"It was quite remarkable," remembers McDonald."

Click on the link in the title for the story and video.

Labels:


 

Webcast on Chronic Pain on MedPageToday

( Posted by-Desinie Smith)

Labels:


 

What's New on Multiple Sclerosis in PubMed

( Posted by-Desinie Smith)
Preclinical testing of strategies for therapeutic targeting of human T-cell trafficking in vivo.
Coisne C, Engelhardt B

Numb chin syndrome: an ominous clinical sign.
Ryba F, Rice S, Hutchison IL

Disease onset in familial and sporadic primary progressive multiple sclerosis.
Koch M, Zhao Y, Yee I, Guimond C, Kingwell E, Rieckmann P, Sadovnick D, Tremlett H

The osteopontin gene +1239A/C single nucleotide polymorphism is associated with type 1 diabetes mellitus in the Italian population.
Chiocchetti A, Orilieri E, Cappellano G, Barizzone N, D Alfonso S, D Annunzio G, Lorini R, Ravazzolo R, Cadario F, Martinetti M, Calcaterra V, Cerutti F, Bruno G, Larizza D, Dianzani U.

Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNâ1A treatment in multiple sclerosis patients.
Contasta I, Totaro R, Berghella AM, Pellegrini P, Del Beato T, Carolei A, Adorno D

NAD(P)H oxidase and pro-inflammatory response during maximal exercise: role of C242T polymorphism of the P22PHOX subunit.
Izzicupo P, Di Valerio V, D' Amico MA, Di Mauro M, Pennelli A, Falone S, Alberti G, Amicarelli F, Miscia S, Gallina S, Di Baldassarre A.

Labels:


Friday

 

MS Patient must remain in prison for growing pot, while appeal is pending

(Posted By: Josi Creek)

Labels:


 

Multiple Sclerosis vein theory has roots in rejected research-VIDEO

(Posted By: Josi Creek)

Labels:


 

BREAKING NEWS: Biogen PML Test Tysabri...PLUS AN ALARMING QUOTE BY A GOVERNMENT EMPLOYEE!

( Posted by-Desinie Smith )




Biogen Seeks Test for Brain Disease Linked to MS Drug (Update1)

By Elizabeth Lopatto
April 9 (Bloomberg) -- Biogen Idec Inc. wants to take the fear out of prescribing its multiple sclerosis treatment Tysabri with a test that can tell patients their odds of getting a deadly brain illness from the drug.

The screening tool could be marketed as early as 2011 if clinical trials involving 9,000 people, set to start this year, show a low rate of false findings, said Naomi Aoki, a spokeswoman for the Cambridge, Massachusetts-based biotechnology company. The test is designed to detect the JC virus that causes progressive multifocal leukoencephalopathy, or PML, a brain-cell destroyer that can lead to disability and death.

Tysabri, which generated $1.1 billion in sales in 2009, has been linked to 42 PML cases, the company has reported. While it’s approved for use only after other drugs fail, 61 percent of 285 neurologists surveyed by RBC Capital Markets in San Francisco said Tysabri’s ability to slow MS progression would make it their first choice if they could assess the risk of PML.

If the test works, it is “absolutely a game changer,” said Patricia O’Looney, vice president of biomedical research at the New York-based National Multiple Sclerosis Society, in a telephone interview. “If Biogen can validate it, that takes out the guessing game.”

‘Longer-Term Positive’

It’s too early to set a dollar amount on the potential gain in drug sales based on such a test until the clinical trials are completed, said Geoffrey Meacham, an analyst for J.P. Morgan in New York, in a telephone interview. A successful test that determines Tysabri is safe to use in some patients would be “a longer-term positive” for the company, he said.

Biogen rose 20 cents to $56.63 at 9:53 a.m. New York time in Nasdaq Stock Exchange composite trading. The stock, which sold for $67.28 on the last trading day before Tysabri was removed from the market, plunged 43 percent on the withdrawal. The shares had fallen 16 percent since Feb. 27, 2005.

Biogen first tested their assay using blood samples taken from 11 patients who later developed PML, said Al Sandrock, senior vice president of neurology research and development. The findings from that study and research on the prevalence of JC virus will be presented next week at the American Academy of Neurology meeting in Toronto.

Behind Goal

Since the therapy returned to the market in 2006, the company hasn’t reached its goal to have 100,000 patients use it by the end of 2010. Tysabri is used by about 48,800 patients as of the end of 2009, according to Biogen. The company backed away from the goal last year, after a fifth patient developed PML.

Biogen plans two clinical trials to determine the rates of false positives and false negatives. For patients who test positive, the risk of PML will be about 1 in 500, said Robert Fox, a neurologist at the Cleveland Clinic in Ohio. For those who test negative, though, the risk is “quite low,” Biogen’s Sandrock said.

In February, the FDA updated Tysabri’s labeling to clarify its risks. The number of infections and deaths from PML remains about 1 in 1,000 overall. The rate is higher outside the U.S., with 2 of every 1,000 patients contracting the illness. The reason for the difference is unknown, the FDA said.

JC Virus

The test is designed to detect the presence of an antibody to the JC virus in the blood of patients, signaling that the patient has been infected.

With a false-negative rate of 2 percent, patients who are free of the virus would lower their risk of getting the brain disorder PML to 1 in 25,000 for the first three years of their Tysabri therapy, wrote analyst Joshua Schimmer of Leerink Swann, in a March 25 note to investors.

Since a patient may become infected with the JC virus at any time (it is passed through the air), part of Biogen’s task in its clinical trials is to determine how many patients become infected over time. This determination changes the odds that any one patient may get the disease.

Probably about 1 to 2 percent of patients will be infected yearly, Sandrock said.

Antibody Reliability
Eugene Major, a researcher at the National Institutes of Health in Bethesda, Maryland, said that when the NIH and others tested for the presence of the virus, rather than antibodies, they found that at least 70 percent of the population probably is infected. The company, based on antibody testing, has put that number at 50 percent.

“They’re underestimating the number of people who’ve been exposed,” Major said in a telephone interview. “We have strong evidence that the overwhelming majority, especially after the third and fourth decade, have been exposed.”

Biogen is looking at other biological signs of PML risk that may be incorporated to improve the test, Sandrock said. In those who test positive, Biogen is testing for markers to further determine which patients are at high risk, Sandrock said. Those markers may include certain genes that increase the risk of a brain infection, or viral mutation that allows JC virus to live in brain tissue.

“We know a lot about the benefits of Tysabri, and we know something about the risk,” said Sandrock. “If we can be specific about an individual’s risk versus an individual’s benefit, that would help patients make better-informed treatment decisions. Patients want to know, ‘what’s my risk?’”

To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net


Click on the headline at the top to read the full story

Labels: , , ,


 

Dr. Sipe Breaks Down Treatments for Multiple Sclerosis- Cladribine


( Posted by-Desinie Smith)
From the article: "Unlike the injections required by other drugs, Sipe said, Cladribine only required eight to ten tablets one to two times a year. Furthermore, in a recent double-blind CLARITY study conducted by Merck Serono, the developing company, Clabridine tablets were shown to significantly suppress the formation of new brain lesions as well prevent relapses. In the study, Clabridine was also shown to be more effective than many of current available treatments. "

Labels:


 

Heidelberg Engineering to introduce tomographer that tracks subtle RNFL changes

(Posted By: Josi Creek)

Labels:


 

PML risk test could boost Biogen's Tysabri—if it works

(Posted By: Josi Creek)

Labels:


 

Examiner Bio New report shows Multiple Sclerosis therapy market to exceed $12.5 billion by 2015

(Posted By: Josi Creek)

 

Medical marijuana is already legal in Illinois & it has been for 3 decades. But it'll take the passage of another law to make it available to patients

(Posted By: Josi Creek)

 

Studies from Various Medical Publications on Multiple Sclerosis

( Posted by-Desinie Smith )

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
Manuel Comabella, Marta Fernández, Roland Martin, Stephanie Rivera-Vallvé, Eva Borrás, Cristina Chiva, Eva Julià, Alex Rovira, Ester Cantó, Jose Carlos Alvarez-Cermeño, Luisa María Villar, Mar Tintoré and Xavier Montalban

Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis
Ingo Kleiter1, Jian Song,Dominika Lukas, Maruf Hasan, Bernhard Neumann, Andrew L. Croxford, Xiomara Pedré,Nadine Hövelmeyer, Nir Yogev, Alexander Mildner , Marco Prinz , Elena Wiese , Kurt Reifenberg , Stefan Bittner , Heinz Wiendl , Lawrence Steinman , Christoph Becker, Ulrich Bogdahn, Markus F. Neurath, Andreas Steinbrecher, and Ari Waisman
Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk
K. C. Simon ScD*, I. A.F. van der Mei PhD, K. L. Munger ScD, A. Ponsonby MD, PhD, J. Dickinson PhD, T. Dwyer MD, P. Sundström MD, PhD, and A. Ascherio MD, DrPH

Clinical trial of a formal group fatigue program in multiple sclerosis
CL Hugos ,LF Copperman , BE Fuller , V. Yadav , J Lovera , and DN Bourdette

Labels:


 

What's New in Multiple Sclerosis on PubMed

( Posted by- Desinie Smith)

Multiple sclerosis: hyperintense lesions in the brain on T1-weighted MR images assessed by diffusion tensor imagingZhou F, Shiroishi M, Gong H, Zee CS
Imaging biomarkers in multiple sclerosis.
Filippi M, Agosta F.

A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, Gallo P, Filippi M.

Chronic cerebrospinal venous insufficiency and multiple sclerosis.
Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R.
okhan@med.wayne.edu


AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
Olney N, Rosen H.

Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by kv1.3 blockers.
Wang T, Lee MH, Johnson T, Allie R, Hu L, Calabresi PA, Nath A.

Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis Velikonja O, Curić K, Ožura A, Jazbec SS.
Differential ICAM-1 isoform expression regulates the development and progression of experimental autoimmune encephalomyelitis Hu X, Barnum SR, Wohler JE, Schoeb TR, Bullard DC
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis Tenorio-Laranga J, Coret-Ferrer F, Casanova-Estruch B, Burgal M, Garcia-Horsman JA.
The pathogenesis of murine coronavirus infection of the central nervous system.
Lane TE, Hosking MP.

T regulatory cells lacking CD25 are increased in MS during relapse.
Fransson M, Burman J, Lindqvist C, Atterby C, Fagius J, Loskog A.


Labels:


Thursday

 

Technology behind nanovaccine may prove widely applicable to treat autoimmune diseases, like multiple sclerosis.

(Posted By: Josi Creek)

 

3D Eye Imaging Enters Neurology Offices

(Posted By: Josi Creek)

HEIDELBERG, Germany - (Business Wire) Heidelberg Engineering is introducing SPECTRALIS®, an office-based imaging device for tracking and measuring axonal change, at the 2010 meeting of the American Academy of Neurology in Toronto. The SPECTRALIS Tracking Laser Tomographer uses its on-board Nsite Axonal Analytics™ to track and measure axonal changes within the retinal nerve fiber layer (RNFL) by capturing high resolution cross-sectional images of the eye.

Numerous peer-reviewed clinical studies have been published in the last several years investigating the relationship between RNFL and neurodegenerative diseases, especially multiple sclerosis. Patients with multiple sclerosis have been shown to have a thinner RNFL than healthy patients, and this is true for patients with and without prior episodes of optic neuritis.1 In addition, RNFL thickness has been shown to correlate with symptoms measured in physical disability scores such as the Expanded Disability Status Scale (EDSS).1

 

Multiple sclerosis forum seeks answers


(Posted By: Josi Creek)

People living with multiple sclerosis had many questions Wednesday about what Canada is doing to test the safety and effectiveness of an unproven surgical treatment and when it might be available in this country.
But the message they got from experts at a Toronto forum was: Be patient and wait for more research.

Labels: ,


 

New MS test for CCSVI comes to the UK

(Posted By: Josi Creek)

Glasgow clinic offering testing for CCSVI – narrowing of veins in the skull which recent studies have linked to MS

Chronic cerebrospinal venous insufficiency (CCSVI) is a hot topic for people with MS at the moment. The new theory is that multiple sclerosis can be caused by blockages in veins draining blood from the brain: Clear the blockages - and MS symptoms may be reduced.

The idea was put forward by an Italian scientist, Dr Paolo Zamboni.

Up until now anyone from the UK wanting to be tested or treated for the condition has had to travel to clinics in Italy or Poland.

Labels:


Wednesday

 

Icahn's Board Push At Genzyme May Hit Antitrust Snag

(Posted By: Josi Creek)

Shareholder activist Carl Icahn's push to gain seats on the board of Genzyme Corp. (GENZ) may face a substantial hurdle: a potential conflict of interest formed by his influence at fellow biotech Biogen Idec Inc. (BIIB).

 

Mayo Clinic Research Provides New Insight into Tissue Damage in Multiple Sclerosis

(Posted By: Josi Creek)

New study brings researchers another step closer to new therapeutic targets for MS.

A new Mayo Clinic study has found that the type of tissue damage changes throughout the course of multiple sclerosis (MS). In early relapsing disease stages, the plaques, or areas where the nervous system is inflamed or demyelinated, are predominantly active with distinct heterogeneous patterns of myelin damage. Later in the chronic progressive phase of the disease, smoldering and inactive plaques predominate, and are characterized by a uniform pattern of tissue damage.


 

Smoking may increase risk of multiple sclerosis: study


(Posted By: Josi Creek)

Smoking may increase the risk of multiple sclerosis in people who have other risk factors for the neurological disorder, researchers said on Wednesday.

The findings suggest that smokers who have high levels of a protein that protects against the Epstein-Barr virus, a common herpes virus, were twice as likely as nonsmokers to get multiple sclerosis (MS), the researchers wrote in the online edition of the journal Neurology.

Labels:


 

Study findings on multiple sclerosis are outlined in reports from Mississippi State University

(Posted By: Josi Creek)

"The data presented in this study were collected in a national survey of 530 informal care givers to people with MS who have greater levels of physical dependency. About 70% of informal care givers responded that assisting the person with MS perform daily activities or personal care took up the largest amount of their care giving time," scientists writing in the journal Disability and Rehabilitation report."

"Care givers also reported a range of home and community-based services that would make care giving easier or improve the care provided. However, informal care givers generally reported low satisfaction with health insurance coverage of these services, especially coverage by health maintenance organizations and other managed care plans," wrote R. Buchanan and colleagues, Mississippi State University.

 

FDA Issues Warning Letters Over Tysabri, ‘Lipodissolve’ Injections


(Posted By: Josi Creek)

The FDA today disclosed several warning letters it had sent to drug makers and weight-loss spas for “false” and-or “misleading” claims for their products. Here’s a rundown:
  • Biogen Idec was cited for a promotional Webcast involving the multiple sclerosis drug Tysabri because it minimized the risk of a serious brain infection, the FDA said. The letter also cited the company for failing to submit the Webcast for FDA review 30 days in advance. Tysabri is sold jointly by Biogen and Elan.
  • Gilead Sciences was cited for a print ad for involving its HIV drug Truvada, which the FDA said overstated the effectiveness of the products and minimized the risks associated with the
    drug.
  • Half a dozen spas offering “lipodissolve” injections to get rid of small fat deposits received letters because the FDA said the therapy hasn’t been cleared by regulators. “The claims made for your lipodissolve products are false and misleading in that they are not supported by substantial evidence or substantial clinical experience,” one letter said.

Labels:


 

Exercise Shown to Reduce Anxiety from Chronic Illness

(Posted By: Josi Creek)

Studies from the University of Georgia, Athens, have revealed that exercise is one way to relieve at least some of the anxiety that come with an assortment of medical conditions—from heart disease to cancer to chronic pain issues.

According to a recent report in Business Week, researchers from the university's department of kinesiology reviewed 40 trials that included 2,914 individuals grappling with a variety of medical conditions, including heart disease, multiple sclerosis, cancer, and chronic pain from arthritis. In 90% of the studies, those assigned an exercise program had fewer symptoms of anxiety (including feelings of worry, apprehension, and nervousness) than did those not assigned to exercise. In those who participated in regular exercise, anxiety symptoms were reduced by 20%. The researchers also discovered that 30 minutes of exercise was more effective in reducing anxiety than shorter periods of exercise, and that exercise programs that lasted 3 to 12 weeks were more effective than programs that ran more than 12 weeks.


 

Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Acad

(Posted By: Josi Creek)

Biogen Idec today announced that 38 company-sponsored platform and poster presentations will be presented during the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 -- 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists. These presentations include data on five compounds that are marketed or currently in development by Biogen Idec and its partners for the treatment of multiple sclerosis (MS), including two approved therapies for MS, TYSABRI(R) (natalizumab) and AVONEX(R) (interferon beta-1a), and three promising compounds in the late stages of development: BG-12 (dimethyl fumarate), PEGylated interferon beta-1a and daclizumab.

Labels: ,


 

New Multiple Sclerosis drug culminates researchers’ long journey-Ampyra

( Posted by- Desinie Smith)

When it became available for prescription this month, a drug heralded as the first medicine to treat the symptoms of multiple sclerosis ( Poster's note:Clarification- Ampyra is the first oral medication said to improve walking speed and leg strength. It's not the first medicine to treat the symptoms of MS.) stirred hope among thousands who suffer from the degenerative illness.For some, it held out the promise of resuming basic tasks like walking to the office copy machine without having to plan ahead. For others, the possibility of running again.For Floyd Davis, the new drug, called Ampyra, delivered relief and satisfaction of a different sort.

Labels: ,


 

Live CCSVI Web Forum

( Posted by- Desinie Smith)
By Julie Stachowiak, Ph.D., About.com Guide to Multiple Sclerosis
On April 14th, the MS Society and the American Academy of Neurology will hold a live web forum about CCSVI and MS. Anyone can attend.
The forum will be at 12:00 pm (noon) Eastern Time. It will last 90 minutes. The panel will consist of the following speakers:
Dr. Paolo Zamboni, Director, Vascular Diseases Center, University of Ferrara, Italy
Dr. Robert Zivadinov, Associate Professor of Neurology at the University at Buffalo, State University of New York
Dr. Andrew Common, Radiologist in Chief at St. Michaels Hospital, University of Toronto, Ontario, CA
Dr. Aaron Miller, Professor of Neurology and Director of the MS Center at Mount Sinai, New York, member of the AAN Board of Directors, Chief Medical Officer of the National MS Society
Here is the information and links you need to participate:
Register now online (12 p.m. ET April 14) and ensure your system will support the live Web forum player. Questions for the panelists can be submitted online in advance of the live Web forum through Facebook or Twitter, or in real time through the live Web forum player. The recorded webcast will be available online after the event for those who are unable to attend.

Labels:


 

Surgery in Poland stunts man's Multiple Sclerosis symptoms

( Posted by-Desinie Smith )
Evan Thornton is teaching himself how to type again.
For years, the Ottawa man's multiple sclerosis had been slowly reducing the number of fingers he could type with, but, after flying to Poland for breakthrough surgery not yet offered in Canada, some symptoms are reversing themselves.

Labels:


 
(Posted by Desinie Smith)

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.


T Vollmer, D Campagnolo, T Tyry, RA Marrie, R Rudick, R Horwitz and G Cutter.

Neurology, March 30, 2010

BACKGROUND: Vascular comorbidity adversely influences health outcomes in several chronic conditions. Vascular comorbidities are common in multiple sclerosis (MS), but their impact on disease severity is unknown. Vascular comorbidities may contribute to the poorly understood heterogeneity in MS disease severity. Treatment of vascular comorbidities may represent an avenue for treating MS.

CONCLUSIONS: Vascular comorbidity, whether present at symptom onset, diagnosis, or later in the disease course, is associated with a substantially increased risk of disability progression in multiple sclerosis. The impact of treating vascular comorbidities on disease progression deserves investigation.

 

WAVE Vibration Therapy Study Shows Improvement in Strength and Motor Skills in Multiple Sclerosis Patients

(Posted By: Josi Creek)

A two-month vibration therapy study in Omaha with 70 Multiple Sclerosis (MS) patients has shown remarkable results. WAVE (Whole-body Advanced Vibration Exercise) technology has improved the patients’ motor skills, decreased spasticity and increased flexibility. For the study, fitness trainers from Comfit Solutions have teamed up with Fast Forward, a conditioning gym, to test how whole-body vibration therapy benefits patients with MS.

Labels:


 

Risk of Sudden Irreversible Disability Low in Multiple Sclerosis-severe attacks occur in just 1 of every 500 relapses

( Posted by- Desinie Smith )

The fear of sudden irreversible disability should not influence therapeutic decisions for patients with multiple sclerosis, say researchers, because such attacks are very rare. And when they occur, they happen whether or not patients are treated with interferons.
Khemissa Bejaoui, PhD, and Loren Rolak, MD, from the Marshfield Clinic in Wisconsin, report that severe attacks occur in just 1 of every 500 relapses.
"Many patients with relapsing disease fear a sudden catastrophic symptom, such as, 'I might wake up paralyzed,'" they point out in their paper. "Some physicians also have anecdotal experience of patients with persistent disability from an acute relapse and may fear delaying or stopping treatment out of concern that a severe deficit could occur."
Severe attacks occur in just 1 of every 500 relapses.
In an accompanying editorial, John Fleming, MD, and Michael Carrithers, MD, from the University of Wisconsin at Madison, complimented the work, saying it should help clinicians with practical problems relating to initial diagnosis and management. They call this a careful study in a real-world setting.
The work appears in the March 16 issue of Neurology.
Source: http://www.medscape.com/viewarticle/719310?src=mp&spon=24&uac=6677SY

Labels:


 

Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology

(Posted By: Josi Creek)

CAMBRIDGE, Mass., Apr 05, 2010 (BUSINESS WIRE) ----Biogen Idec (NASDAQ: BIIB) today announced that 38 company-sponsored platform and poster presentations will be presented during the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 -- 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists. These presentations include data on five compounds that are marketed or currently in development by Biogen Idec and its partners for the treatment of multiple sclerosis (MS), including two approved therapies for MS, TYSABRI(R) (natalizumab) and AVONEX(R) (interferon beta-1a), and three promising compounds in the late stages of development: BG-12 (dimethyl fumarate), PEGylated interferon beta-1a and daclizumab.

Labels: ,


 

Copaxone Immediate Post-Injection Reaction Side Effect

( Posted by-Desinie Smith)

By Julie Stachowiak, Ph.D., About.com Guide to Multiple Sclerosis
Although I have been on Copaxone (glatiramer acetate) for my relapsing-remitting multiple sclerosis (RRMS) for almost 4 years, I have not experienced this side effect from my injections. Nor do I want to, based on what I have heard.

Labels:


 

Studies from Various Medical Publications on Multiple Sclerosis

( Posted by -Desinie Smith)

Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis.I Kleiter, J Song, D Lukas, M Hasan, B Neumann, AL Croxford, X Pedre, N Hovelmeyer, N Yogev, A Mildner, M Prinz, E Wiese, K Reifenberg, S Bittner, H Wiendl, L Steinman, C Becker, U Bogdahn, MF Neurath, A Steinbrecher, and A WaismanBrain, March 30, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20354004

Interleukin 18 Receptor 1 expression distinguishes patients with multiple sclerosis.A Gillett, M Thessen Hedreul, M Khademi, A Espinosa, AD Beyeen, M Jagodic, I Kockum, RA Harris, and T OlssonMultiple Sclerosis, March 30, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20354066

Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study.S Lo Fermo, R Barone, F Patti, P Laisa, TL Cavallaro, A Nicoletti, and M ZappiaMultiple Sclerosis, March 29, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20350959

High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre10-yearexperience.E Krasulova, M Trneny, T Kozak, B Vackova, D Pohlreich, D Kemlink, P Kobylka, I Kovarova, P Lhotakova, and E HavrdovaMultiple Sclerosis, March 29, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20350962

Time domain and spectral domain optical coherence tomography in multiple sclerosis: A comparative cross-sectional study.M Bock, AU Brandt, J Dorr, CF Pfueller, S Ohlraun, F Zipp, and F PaulMultiple Sclerosis, March 29, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20350961

Strains of Epstein-Barr virus infecting multiple sclerosis patients.R Brennan, J Burrows, M Bell, L Bromham, P Csurhes, A Lenarczyk, J Sverndal, J Klintenstedt, M Pender, and S BurrowsMultiple Sclerosis, March 29, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20350958

Lesional magnetization transfer ratio:a feasible outcome for remyelinating treatment trials in multiple sclerosis.I van den Elskamp, D Knol, H Vrenken, G Karas, A Meijerman, M Filippi, L Kappos, F Fazekas, K Wagner, C Pohl, R Sandbrink, C Polman, B Uitdehaag, and F BarkhofMultiple Sclerosis, March 29, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20350960

An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmacytoid Dendritic Cells Characterizes the Dysfunctional Immune Regulation in Multiple Sclerosis.N Schwab, AL Zozulya, BC Kieseier, KV Toyka, and H WiendlJ Immunol, March 31, 2010
http://highwire.stanford.edu/cgi/medline/pmid;20357264

Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis
http://www.neurology.org/cgi/content/abstract/74/14/1127?ct=ct

Labels:


Tuesday

 

High-Risk Pools Will Tackle Preexisting Conditions

(Posted By: Josi Creek)

Having MS, I know the importance of having medical insurance, and what no insurance can do to someone with a pre-existing condition. Medical insurance for a patient with multiple sclerosis is more than important. It can extend the years of mobility that person has by providing disease modifying drugs, and it can give them access to important tests such as MRI's, and blood tests. Those tests without insurance are not affordable to the average income person, and many people with MS are unable to work, therefore, unable to even see a neruologist to order these tests. Insurance also provides medications that manage some of the painful symptoms that come with the disease.

WASHINGTON -- Taking its first action under the healthcare reform law, the Obama Administration announced that it will help states establish temporary high-risk pools to provide health insurance to people who cannot obtain it due to preexisting medical conditions.

Health and Human Services Secretary Kathleen Sebelius announced the plan in a letter to governors and independent insurance commissioners.

Sebelius asked the state officials to indicate their state's interest in participating in the temporary high risk pool program, which is part of the healthcare reform law.

The law provides $5 billion to fund the program from July 1, 2010 through January 1, 2014. Money will be allocated based on each state's population as well as its costs.


 

"THE STUPIDEST THING I'VE EVER DONE... SO FAR...I was convinced that this would "cure" me."




Hi Stan,
It was about a year ago in the spring, and my MS was really getting me down. I was desperate to try anything to recover, and at the time, the Rebif that I was taking didn't seem to be helping my situation any. I was walking very slowly, and both of my hands had curled up, and were difficult to use. I am an artist, so poorly functioning hands were devistating to me.

I had seen on the internet, several people stinging themselves with bees, claiming that it was the "cure" for multiple sclerosis. Many of them were jumping and running around as if they had never been sick at all. I was more than jealous. I had to try it.

A few weeks later, I found a bees nest in my garden. "Hmm.. this could be my gateway to recovery" I thought to myself. All that I needed to do was get them to sting me. I quickly thought up a plan. After grabbing a very loud air horn, and my camera of course, I headed out to the bee hive, thinking to myself that a cure was right around the corner. I walked slowly to the bees nest, a bit hesitant, nervous about what it would feel like to be stung. I had never been stung by a bee before. I thought to myself.. "well, there's a first time for everything", and blasted the horn right into the hive.

The bees came flying out of the hive, angry, and came rushing right toward me. I think I did a good job aggitating them because I got my first sting within a few seconds. A few more followed. It was quite painful, but I managed to grab my camera and start snapping photographs to take my mind off of the pain. The one blurry photograph that I got was of a bee, right as it was about to sting me. When I was done taking photographs, I headed indoors, in pain, with large welts forming on various parts of my body. It didn't matter to me.
I was convinced that this would "cure" me. I can't believe I was so foolish.

The next day, I was covered with welts, and felt horrible. I had really bad fatigue, and my arms and legs were going more numb than before. My symptoms continued getting worse for about 3 weeks, and by the end of the month, I finally began to recover. It turns out that the bee stings flaired me up pretty badly. So much for that "miracle cure". I'm never doing anything that stupid again.

Here is a link to the story that I read about bee stings Stan:
http://www.foxnews.com/story/0,2933,590407,00.html

1,500 Bee Stings Helps MS Patient Walk Again

A 45-year-old U.K. woman who suffers from multiple sclerosis, says bee stings helped her regain her quality of life, London's Daily Mail reported. Sami Chugg was confined to her bed and unable to move, but after the area around her spine was deliberately stung by 1,500 bees, she feels much better and can walk again. Bee venom therapy is known in some cultures to relieve the body of pain by reducing inflammation.

CLICK HERE TO READ 1000'S OF OTHER STORIES ABOUT OUR 2,700 Facebook FRIENDS LIKE JOSI'S :

Labels:



Go to Newer News Go to Older News